Previous 10 | Next 10 |
– Investment Reinforces Companies’ Conviction in TIGIT Pathway and Provides Opportunity to Accelerate the Anti-TIGIT Program – – Additional Equity Investment of $320M, Raising Gilead’s Ownership Stake in Arcus to 33% – – Ame...
2024-01-29 12:52:58 ET More on NanoViricides Seeking Alpha’s Quant Rating on NanoViricides Historical earnings data for NanoViricides Financial information for NanoViricides Read the full article on Seeking Alpha For further details see: Na...
2024-01-29 10:43:48 ET More on HOOKIPA Pharma Hookipa Pharma stock soars on $21.25M equity investment from Gilead HOOKIPA Pharma GAAP EPS of -$0.17 beats by $0.03, revenue of $6.87M beats by $2.62M Seeking Alpha’s Quant Rating on HOOKIPA Pharma Histori...
2024-01-29 07:30:00 ET Summary Rob Isbitts discusses the state of ETF business and the recent launch of spot Bitcoin ETFs. Why he's currently looking at the dividend space. Pros and cons of owning dividend ETFs; managing risk in dividend investing. Listen below or on...
2024-01-28 12:00:53 ET More on Amgen, Vertex Pharma, etc. Biotech And Pharma Diversification Pays Off Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar...
2024-01-26 07:16:34 ET More on Cigna, CVS Health, etc. Humana: The $300 Level Could Get Taken Out In The Near Future Humana Inc. (HUM) Q4 2023 Earnings Call Transcript CVS Health: Back In The Buy Column Humana gets downgrade at Deutsche Bank as stock nears fo...
2024-01-25 08:00:00 ET Summary Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected. Competitive stories in gene editin...
2024-01-24 10:33:18 ET More on Gilead Sciences Gilead's Dividend Growth Potential Looks Phenomenal Without A Clear Growth Path, Gilead Sciences Is A Hold Gilead in selloff after late-stage setback for Trodelvy Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2023 financial results and guidance will be released on Tuesday, February 6, 2024 after the market closes. At 5:00 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the c...
NORTHAMPTON, MA / ACCESSWIRE / January 23, 2024 / For the past 30 years, Pilar Fernandez has navigated living with metastatic breast cancer. And while she's faced a series of related health challenges, it hasn't slowed her down. Instead, Pilar's experience and desire to help others motivated he...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...